Olendalizumab Biosimilar - Research Grade

Human

C5ï؟½

5mg/ml

IgG2-G4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P01031

Blue ice

Complement component C5 sits at the convergence point of the terminal complement cascade and is a longstanding target in inflammation research. This recombinant antibody is an unconjugated, non-therapeutic analog of olendalizumab, expressed in CHO cells against human C5 on a hybrid IgG2/IgG4 kappa framework. Released for research use only, it is delivered in a low-endotoxin format suited to in vivo studies and supplied in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. It supports complement-inhibition assays, functional hemolytic readouts, and preclinical inflammatory-disease models. Uniform quality across lots underpins confident comparisons in long-running projects.

REGN3918,REGN-3918,complement 5, C5a anaphylatoxin

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks